TNF-alpha inhibitors

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3072
R4704
Duricova, 2019 Low birth weight (weight < 2500g) during pregnancy (anytime or not specified) retrospective cohort unexposed, disease free Adjustment: No 2.96 [0.30;29.13] C 3/72   1/69 4 72
ref
S3066
R4669
Chaparro, 2018 Low birth weight (<2,500 mg) 3 months (or more) before pregnancy or during pregnancy excluded retrospective cohort unexposed, sick Adjustment: No 1.61 [0.99;2.62] C
excluded (exposition period)
41/388   31/453 72 388
ref
S3123
R4857
De Lima, 2018 Low birth weight (NOS) at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.79 [0.01;43.11] C 0/15   0/12 0 15
ref
S4098
R8759
Carman - Etanercept (Controls unexposed, disease free), 2017 Birth weight <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, disease free excluded Adjustment: No 2.20 [1.41;3.44] C
excluded (control group)
31/217   76/1,081 107 217
ref
S4099
R8774
Carman - Etanercept (Controls unexposed, sick), 2017 Birth weight <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: No 1.71 [1.14;2.58] C 31/217   172/1,940 203 217
ref
S4106
R8799
Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Birth weight (≤10th centile) at least 1st trimester prospective cohort unexposed, sick Adjustment: No 0.73 [0.33;1.62] -/-   -/- - -
ref
S3070
R4686
De Lima (Controls unexposed, disease free), 2016 Low birth weight (birth weight lower than 2500 g) 1st and 2nd trimester prospective cohort unexposed, disease free excluded Adjustment: No 2.85 [1.26;6.46] C
excluded (control group)
8/83   29/804 37 83
ref
S3071
R4695
De Lima (Treatment stopped during pregnancy, sick), 2016 Low birth weight (birth weight lower than 2500 g) 1st and 2nd trimester prospective cohort unexposed, sick Adjustment: No 0.95 [0.21;4.29] C 3/32   5/51 8 32
ref
S13735
R53499
Komoto, 2016 Low birth weight (<2500G) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.97 [0.24;3.95] C 4/17   7/29 11 17
ref
S2888
R4119
Weber-Schoendorfer, 2015 Low birth weight (<2500 g) 1st trimester prospective cohort unexposed, disease free Adjustment: No 13.45 [7.36;24.59] C 51/399   14/1,299 65 399
ref
S3037
R4571
Seirafi, 2014 Low birth weight (< 2500 g) 3 months (or more) before pregnancy or during pregnancy excluded retrospective cohort unexposed, sick Adjustment: No before conception and/or during pregnancy 1.73 [0.74;4.02] C
excluded (exposition period)
19/118   9/90 28 118
ref
S3017
R4515
Schnitzler (Controls unexposed, disease free), 2011 Low birth weight (<2500g) 3 months (or more) before pregnancy or during pregnancy prospective cohort unexposed, disease free excluded Adjustment: No before conception and/or during pregnancy 1.98 [0.55;7.16] C
excluded (control group)
6/32   5/48 11 32
ref
S3018
R4520
Schnitzler (Unexposed control, sick), 2011 Low birth weight (<2500g) 3 months (or more) before pregnancy or during pregnancy excluded prospective cohort unexposed, sick Adjustment: No before conception and/or during pregnancy 1.44 [0.46;4.46] C
excluded (exposition period)
6/32   9/65 15 32
ref
Total 7 studies 1.86 [0.66;5.25] 291 752
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Duricova, 2019Duricova, 2019 2.96[0.30; 29.13]47210%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA De Lima, 2018De Lima, 2018 0.79[0.01; 43.11]0155%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Carman - Etanercept (Controls unexposed, sick), 2017Carman - Etanercept, 2017 1 1.71[1.14; 2.58]20321719%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017Chambers - Adalimumab, 2017 2 0.73[0.33; 1.62]--18%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA De Lima (Treatment stopped during pregnancy, sick), 2016De Lima, 2016 3 0.95[0.21; 4.29]83214%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Komoto, 2016Komoto, 2016 0.97[0.24; 3.95]111715%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Weber-Schoendorfer, 2015Weber-Schoendorfer, 2015 13.45[7.36; 24.59]6539919%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (7 studies) I2 = 87% 1.86[0.66; 5.25]2917520.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls unexposed, sick, ADA only; 3: Treatment stopped during pregnancy, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.86[0.66; 5.25]29175287%NADuricova, 2019 De Lima, 2018 Carman - Etanercept (Controls unexposed, sick), 2017 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 De Lima (Treatment stopped during pregnancy, sick), 2016 Komoto, 2016 Weber-Schoendorfer, 2015 7 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 9.58[2.78; 33.04]6947137%NADuricova, 2019 Weber-Schoendorfer, 2015 2 unexposed, sickunexposed, sick 1.23[0.76; 1.98]22226625%NACarman - Etanercept (Controls unexposed, sick), 2017 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 De Lima (Treatment stopped during pregnancy, sick), 2016 Komoto, 2016 4 exposed to other treatment, sickexposed to other treatment, sick 0.79[0.01; 43.11]-15 -NADe Lima, 2018 1 Tags Adjustment   - No  - No 1.86[0.66; 5.25]29175287%NADuricova, 2019 De Lima, 2018 Carman - Etanercept (Controls unexposed, sick), 2017 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 De Lima (Treatment stopped during pregnancy, sick), 2016 Komoto, 2016 Weber-Schoendorfer, 2015 7 All studiesAll studies 1.86[0.66; 5.25]29175287%NADuricova, 2019 De Lima, 2018 Carman - Etanercept (Controls unexposed, sick), 2017 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 De Lima (Treatment stopped during pregnancy, sick), 2016 Komoto, 2016 Weber-Schoendorfer, 2015 70.250.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.85.42.4460.000Duricova, 2019De Lima, 2018Carman - Etanercept (Controls unexposed, sick), 2017Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017De Lima (Treatment stopped during pregnancy, sick), 2016Komoto, 2016Weber-Schoendorfer, 2015

Asymetry test p-value = 0.7121 (by Egger's regression)

slope=1.1323 (0.8028); intercept=-0.7861 (2.0119); t=0.3907; p=0.7121

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 3017, 3070, 4098

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 4.17[1.44; 12.08]21377187%NADuricova, 2019 Carman - Etanercept (Controls unexposed, disease free), 2017 De Lima (Controls unexposed, disease free), 2016 Weber-Schoendorfer, 2015 4 unexposed, sick controlsunexposed, sick controls 1.23[0.76; 1.98]22226625%NACarman - Etanercept (Controls unexposed, sick), 2017 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 De Lima (Treatment stopped during pregnancy, sick), 2016 Komoto, 2016 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.79[0.01; 43.11]-15 -NADe Lima, 2018 10.510.01.0